Amentum Holdings, Inc.
AMTMAmentum Holdings, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is building a base (16 weeks in) while the P/E sits at the 18th percentile of its own 1-year range. Underneath, the last four quarters read mixed, and 878% of the last 2 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Amentum Holdings, Inc. trades at $24.1, building a base and 16 weeks into that stage. That is −8.9% against its own 200-day average. It sits at 23% of a 52-week range of $20 to $38. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (22 weeks and counting).
Today the stock is building a base — week 16 of stage 1. At $24.1 it trades −8.9% versus its 200-day average and sits at 23% of its 52-week range ($20–$38).
Against the market, two honest reads. Cumulative: over the last 1.9 years the stock moved −6% while the S&P 500 moved +35% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (22 weeks and counting; last ahead the week of 2026-03-06) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Amentum Holdings, Inc. trades at 40.3× P/E, near the bottom of its own range — cheaper only 18% of the time. Its long-run median P/E is 72.2×, measured across 1.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 40.3× is near the bottom of its own range — cheaper only 18% of the time, against a long-run median of 72.2× measured over 1.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Amentum Holdings, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +71.5% | +23.3% | — | — |
| Stock price | −0.1% | — | — | — |
4-Factor Sector Score
41.2/100 — rank 20 of 30 in Specialty Business Services · 58% evidence confidence
Amentum Holdings, Inc. scores 41.2 out of 100 against the 30 companies it is compared with in Specialty Business Services, ranking 20. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 19.8 + 9 + 9.2 + 3.2 = 41.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Amentum Holdings, Inc. reported $3.5 B of revenue in the Apr 26 quarter, −0.3% year on year. Over 4 years it has compounded at 25.0% a year. The last full year, FY25, came in at $14.4 B. The last four reported quarters add to $14.2 B.
FY25 revenue came in at $14.4 B (+71.5% on the year), capping 4 years at 25.0% compound. The latest quarter (Apr 26) printed $3.5 B, −0.3% year on year.
Pace check: the last four quarters averaged +47.8% growth against the decade's 25.0% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Amentum Holdings, Inc.'s operating margin is 4.3% in the Apr 26 quarter, +1.1 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 0.8% to 3.5%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 4.3%, +1.1 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 0.8%–3.5%.
Why the margin moved: operating margin went +1.1 pp year on year while gross margin went −0.8 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Amentum Holdings, Inc. earned $0.1 B of net profit in the Apr 26 quarter. Full-year FY25 profit was $0.1 B. The 4-year compound rate is 18.9%. That is 1.4% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 4 of the last 11 reported quarters were loss-making.
Apr 26 profit was $0.1 B, null year on year. On the full year, FY25 printed $0.1 B (null), and the 4-year compound rate is 18.9%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 2 fiscal years 878% of Amentum Holdings, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.5 B of operating cash against $0.1 B of profit. After $0.0 B of capital spending, $0.5 B was left as free cash.
FY25: operating cash of $0.5 B against reported profit of $0.1 B, leaving free cash of $0.5 B after $0.0 B of capital spending. Across the last 2 fiscal years the conversion rate is 878% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Amentum Holdings, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Amentum Holdings, Inc. earns a ROE of 1% in FY25. That is up from a trough of −76% in FY23. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 0.4% net margin on 1.26× asset turns.
FY25 ROE is 1%, recovered from a FY23 trough of −76% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 0.4% net margin × 1.26× asset turns × 2.38× balance-sheet leverage ≈ 1.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
Dividend
Amentum Holdings, Inc. pays no dividend. Across the last 11 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Amentum Holdings, Inc. does not currently pay a dividend. Across the last 11 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Amentum Holdings, Inc. carries total debt of $3.9 B against shareholder equity of $4.7 B as of Apr 26, a debt-to-equity of 0.84. On the annual view that ratio went from 6.25 in FY22 to 0.82 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Apr 26: total debt of $3.9 B against shareholder equity of $4.7 B — a debt-to-equity of 0.84. On the annual view, debt-to-equity went from 6.25 (FY22) to 0.82 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
8.8% of Amentum Holdings, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 6.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 8.8% of the float is sold short, and at typical trading volumes it would take about 6.5 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Amentum Holdings, Inc.: the Z-score reads 2.07. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.07 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.07.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1First Advantage CorporationFA | 61.8/100Mixed-positive evidence64% evidence | LEADER | 24.6/35 Revenue 53.4% · PAT — · OPM change 6.6 pp 62% evidence | 9.5/25 ROCE 0.9% · OPM 8.7% 76% evidence | 8.5/20 P/E 294× · PEG — 15% evidence | 19.2/20 RS sector 19.9% · RS bench 26% · 1Y 24.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 9.5 + 8.5 + 19.2 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2ABM Industries IncorporatedABM | 60.4/100Mixed-positive evidence85% evidence | BREAKING OUT | 22.3/35 Revenue 6.5% · PAT 100% · OPM change -0.1 pp 95% evidence | 11.4/25 ROCE 2.1% · OPM 3.8% 76% evidence | 15.0/20 P/E 15.7× · PEG 0.38 65% evidence | 11.7/20 RS sector -4.5% · RS bench 0.4% · 1Y 3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 11.4 + 15 + 11.7 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3AramarkARMK | 59.2/100Thin evidence · provisional58% evidence | LEADER | 20.0/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 12.4/25 ROCE 2.1% · OPM 4.5% 76% evidence | 9.7/20 P/E 32× · PEG — 15% evidence | 17.1/20 RS sector 11% · RS bench 16.6% · 1Y 41.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 12.4 + 9.7 + 17.1 = 59.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Cintas CorporationCTAS | 57.1/100Thin evidence · provisional58% evidence | TURNING | 20.2/35 Revenue — · PAT — · OPM change -0.2 pp 45% evidence | 17.1/25 ROCE 8.4% · OPM 23.2% 76% evidence | 9.6/20 P/E 34.9× · PEG — 15% evidence | 10.2/20 RS sector -8.3% · RS bench -3.5% · 1Y -10%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 17.1 + 9.6 + 10.2 = 57.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5AZZ Inc.AZZ | 55.2/100Mixed-positive evidence85% evidence | ASLEEP | 18.6/35 Revenue 5.7% · PAT -23.9% · OPM change 0.7 pp 95% evidence | 13.8/25 ROCE 3.9% · OPM 17.2% 76% evidence | 10.7/20 P/E 20.7× · PEG 1.43 65% evidence | 12.1/20 RS sector 4.6% · RS bench 9.9% · 1Y 38.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 13.8 + 10.7 + 12.1 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Quad/Graphics, Inc.QUAD | 54.7/100Thin evidence · provisional52% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change -0.1 pp 45% evidence | 9.3/25 ROCE 2.2% · OPM 3% 76% evidence | 11.1/20 P/E 13.4× · PEG — 15% evidence | 17.0/20 RS sector 31.4% · RS bench 37.8% · 1Y 69.3%5 of 12 weeks ahead 70% evidence |
| Exact sum: 17.3 + 9.3 + 11.1 + 17 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7CBIZ, Inc.CBZ | 53.6/100Thin evidence · provisional58% evidence | BREAKING OUT | 14.3/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence | 10.7/25 ROCE 0.8% · OPM 23.2% 76% evidence | 10.9/20 P/E 15× · PEG — 15% evidence | 17.7/20 RS sector 8.2% · RS bench 14% · 1Y -12.8%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.3 + 10.7 + 10.9 + 17.7 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Maximus, Inc.MMS | 52.2/100Mixed-positive evidence81% evidence | BASING | 18.8/35 Revenue -1.5% · PAT 23.9% · OPM change 0.2 pp 83% evidence | 14.3/25 ROCE 4.2% · OPM 11.4% 76% evidence | 16.4/20 P/E 9.6× · PEG 0.29 65% evidence | 2.7/20 RS sector -29.4% · RS bench -25.6% · 1Y -22.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 14.3 + 16.4 + 2.7 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Cimpress plcCMPR | 51.2/100Thin evidence · provisional58% evidence | LEADER | 16.3/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 11.2/25 ROCE 4.9% · OPM 5.5% 76% evidence | 9.9/20 P/E 26.8× · PEG — 15% evidence | 13.8/20 RS sector 14.3% · RS bench 20% · 1Y 85.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 11.2 + 9.9 + 13.8 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Global Payments Inc.GPN | 49.8/100Mixed-negative evidence81% evidence | BREAKING OUT | 12.9/35 Revenue 14.8% · PAT -55.2% · OPM change -20.9 pp 83% evidence | 7.7/25 ROCE 0% · OPM -0.5% 76% evidence | 15.6/20 P/E 13.4× · PEG 0.34 65% evidence | 13.6/20 RS sector -2.2% · RS bench 3% · 1Y 9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 7.7 + 15.6 + 13.6 = 49.8 · Decision use: Price leads the evidence: RS versus the benchmark is 3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 11RB Global, Inc.RBA | 48.9/100Mixed-negative evidence81% evidence | TURNING | 21.1/35 Revenue 9.5% · PAT 7.3% · OPM change 0.5 pp 83% evidence | 15.7/25 ROCE 7.5% · OPM 17.6% 76% evidence | 4.3/20 P/E 44.1× · PEG 7.47 65% evidence | 7.8/20 RS sector -11% · RS bench -6.4% · 1Y -2.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 15.7 + 4.3 + 7.8 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Cass Information Systems, Inc.CASS | 48.9/100Thin evidence · provisional58% evidence | BREAKING OUT | 17.2/35 Revenue — · PAT — · OPM change -7.1 pp 45% evidence | 4.4/25 ROCE -3.2% · OPM -37% 76% evidence | 10.7/20 P/E 18.5× · PEG — 15% evidence | 16.6/20 RS sector 8.5% · RS bench 14% · 1Y 38.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 4.4 + 10.7 + 16.6 = 48.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13UniFirst CorporationUNF | 47.8/100Mixed-negative evidence85% evidence | TURNING | 10.7/35 Revenue 1.4% · PAT -24.3% · OPM change -4.3 pp 95% evidence | 10.4/25 ROCE 0.9% · OPM 3.6% 76% evidence | 11.3/20 P/E 41.9× · PEG 1.23 65% evidence | 15.4/20 RS sector 13.1% · RS bench 18.6% · 1Y 68.7%4 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 10.4 + 11.3 + 15.4 = 47.8 · Decision use: Price leads the evidence: RS versus the benchmark is 18.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14UL Solutions Inc.ULS | 47.3/100Mixed-negative evidence81% evidence | ASLEEP | 23.7/35 Revenue 6.9% · PAT 4.2% · OPM change 2.7 pp 83% evidence | 16.2/25 ROCE 6.7% · OPM 18.2% 76% evidence | 4.9/20 P/E 50.1× · PEG 4 65% evidence | 2.5/20 RS sector -18.4% · RS bench -14.2% · 1Y 17.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 16.2 + 4.9 + 2.5 = 47.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.4% and the one-year return is 17.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 15Thomson Reuters CorporationTRI | 47.3/100Mixed-negative evidence81% evidence | TURNING | 18.9/35 Revenue 5.4% · PAT -25.9% · OPM change 1 pp 83% evidence | 16.0/25 ROCE 4.3% · OPM 30.6% 76% evidence | 5.5/20 P/E 26.6× · PEG 4.61 65% evidence | 6.9/20 RS sector -22.7% · RS bench -18.5% · 1Y -40.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 16 + 5.5 + 6.9 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Dolby Laboratories, Inc.DLB | 47.3/100Thin evidence · provisional58% evidence | TURNING | 16.6/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence | 13.6/25 ROCE 1.2% · OPM 28.5% 76% evidence | 10.2/20 P/E 22.8× · PEG — 15% evidence | 6.9/20 RS sector -17.4% · RS bench -13% · 1Y -15.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 13.6 + 10.2 + 6.9 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Eastman Kodak CompanyKODK | 47.3/100Thin evidence · provisional58% evidence | ASLEEP | 20.6/35 Revenue 4.4% · PAT -317.5% · OPM change 4.9 pp 62% evidence | 6.8/25 ROCE -0.1% · OPM -0.4% 76% evidence | 11.3/20 P/E 12.9× · PEG — 15% evidence | 8.6/20 RS sector -7.4% · RS bench -2.8% · 1Y 26.8%4 of 12 weeks ahead 70% evidence |
| Exact sum: 20.6 + 6.8 + 11.3 + 8.6 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Transcat, Inc.TRNS | 47.0/100Mixed-negative evidence75% evidence | TURNING | 12.8/35 Revenue 18.6% · PAT -61.5% · OPM change -4.2 pp 83% evidence | 10.1/25 ROCE 1.1% · OPM 4.8% 76% evidence | 9.7/20 P/E 125.1× · PEG 1.35 65% evidence | 14.4/20 RS sector 6% · RS bench 11.4% · 1Y 16.1%8 of 12 weeks ahead 70% evidence |
| Exact sum: 12.8 + 10.1 + 9.7 + 14.4 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 11.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 19Copart, Inc.CPRT | 41.4/100Mixed-negative evidence85% evidence | BASING | 16.8/35 Revenue 1.1% · PAT 5% · OPM change 0.2 pp 95% evidence | 16.6/25 ROCE 5.2% · OPM 37.5% 76% evidence | 6.6/20 P/E 20.6× · PEG 3.47 65% evidence | 1.4/20 RS sector -33.8% · RS bench -30.3% · 1Y -36.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 16.6 + 6.6 + 1.4 = 41.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 20Amentum Holdings, Inc.this pageAMTM | 41.2/100Thin evidence · provisional58% evidence | BASING | 19.8/35 Revenue — · PAT — · OPM change 1.4 pp 45% evidence | 9.0/25 ROCE 1.6% · OPM 4.3% 76% evidence | 9.2/20 P/E 45.1× · PEG — 15% evidence | 3.2/20 RS sector -21.2% · RS bench -17.1% · 1Y -3.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 9 + 9.2 + 3.2 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Target Hospitality Corp.TH | 37.9/100Mixed-negative evidence64% evidence | FADING | 9.3/35 Revenue -7.4% · PAT -197.8% · OPM change -18.2 pp 62% evidence | 5.6/25 ROCE -2.9% · OPM -19.7% 76% evidence | 9.0/20 P/E 71.2× · PEG — 15% evidence | 14.0/20 RS sector 25.2% · RS bench 30.9% · 1Y 89.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 9.3 + 5.6 + 9 + 14 = 37.9 · Decision use: Price leads the evidence: RS versus the benchmark is 30.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22LegalZoom.com, Inc.LZ | 37.5/100Mixed-negative evidence75% evidence | BREAKING OUT | 10.3/35 Revenue 12.9% · PAT -60% · OPM change -3.6 pp 83% evidence | 8.6/25 ROCE 1.5% · OPM 1.3% 76% evidence | 12.0/20 P/E 94.5× · PEG 0.93 65% evidence | 6.6/20 RS sector -13.7% · RS bench -9% · 1Y -23.5%6 of 12 weeks ahead 70% evidence |
| Exact sum: 10.3 + 8.6 + 12 + 6.6 = 37.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23BrightView Holdings, Inc.BV | 35.3/100Mixed-negative evidence65% evidence | ASLEEP | 12.9/35 Revenue 0% · PAT 2.2% · OPM change -1.1 pp 83% evidence | 7.5/25 ROCE 0.6% · OPM 2.3% 76% evidence | 8.7/20 P/E 103.1× · PEG — 15% evidence | 6.2/20 RS sector -14.2% · RS bench -9.8% · 1Y -13.6%6 of 12 weeks ahead 70% evidence |
| Exact sum: 12.9 + 7.5 + 8.7 + 6.2 = 35.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Resolute Holdings Management, Inc.RHLD | 33.7/100Adverse evidence62% evidence | TURNING | 10.5/35 Revenue 82.2% · PAT -83.2% · OPM change -26 pp 83% evidence | 7.3/25 ROCE -0.2% · OPM -1.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.9/20 RS sector -16.2% · RS bench -11.9% · 1Y 177.9%2 of 12 weeks ahead 70% evidence |
| Exact sum: 10.5 + 7.3 + 10 + 5.9 = 33.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25TIC Solutions, Inc.TIC | 31.2/100Thin evidence · provisional53% evidence | ASLEEP | 14.9/35 Revenue — · PAT — · OPM change -2 pp 39% evidence | 4.7/25 ROCE -1% · OPM -6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.6/20 RS sector -27.4% · RS bench -23.4% · 1Y -11.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 4.7 + 10 + 1.6 = 31.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26BlackSky Technology Inc.BKSY | 29.7/100Thin evidence · provisional55% evidence | ASLEEP | 9.0/35 Revenue -9.3% · PAT — · OPM change -48.7 pp 62% evidence | 3.8/25 ROCE -6.5% · OPM -89.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.9/20 RS sector -12.6% · RS bench -8.3% · 1Y 48.7%4 of 12 weeks ahead 70% evidence |
| Exact sum: 9 + 3.8 + 10 + 6.9 = 29.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Spire Global, Inc.SPIR | 26.7/100Adverse evidence64% evidence | ASLEEP | 7.1/35 Revenue -36% · PAT — · OPM change -36.7 pp 62% evidence | 3.1/25 ROCE -30.4% · OPM -155.2% 76% evidence | 11.5/20 P/E 8.3× · PEG — 15% evidence | 5.0/20 RS sector -8% · RS bench -3.6% · 1Y 40.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 7.1 + 3.1 + 11.5 + 5 = 26.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28RELX PLCRELX | 52.3/100Thin evidence · provisional43% evidence | TURNING | 18.9/35 Revenue — · PAT — · OPM change — 12% evidence | 16.1/25 ROCE 9.3% · OPM — 61% evidence | 10.5/20 P/E 19.2× · PEG — 15% evidence | 6.8/20 RS sector -18.5% · RS bench -14.2% · 1Y -23.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 16.1 + 10.5 + 6.8 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Public Policy Holding Company, Inc.PPHC | 44.5/100Thin evidence · provisional11% evidence | 17.5/35 Revenue — · PAT — · OPM change — 0% evidence | 7.0/25 ROCE -11.5% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 17.5 + 7 + 10 + 10 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Rentokil Initial plcRTO | 42.1/100Thin evidence · provisional43% evidence | ASLEEP | 18.1/35 Revenue — · PAT — · OPM change — 12% evidence | 12.7/25 ROCE 1.8% · OPM — 61% evidence | 9.8/20 P/E 30.3× · PEG — 15% evidence | 1.5/20 RS sector -27% · RS bench -23.2% · 1Y -0.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 12.7 + 9.8 + 1.5 = 42.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Amentum Holdings, Inc.'s stock price today?
Amentum Holdings, Inc. trades at $24.1, −0.1% over the past year. The company is valued at $6.0 B. The stock sits at 23% of its 52-week range of $20–$38, −8.9% versus its 200-day average. On the tape, the price is building a base, 16 weeks in. — as of 5 August 2026.
What were Amentum Holdings, Inc.'s latest quarterly results?
Amentum Holdings, Inc. reported revenue of $3.5 B and net profit of $0.1 B for the Apr 26 quarter. Earnings per share were $0.22. The operating margin was 4.3%, 1.1 pp higher than a year earlier. — as of 5 August 2026.
What is Amentum Holdings, Inc.'s revenue?
Amentum Holdings, Inc. reported revenue of $3.5 B in the Apr 26 quarter, −0.3% year on year. For the full FY25 fiscal year, revenue was $14.4 B (+71.5%). Over the last 4 years revenue compounded at 25.0% a year. — as of 5 August 2026.
What is Amentum Holdings, Inc.'s profit?
Amentum Holdings, Inc. earned $0.1 B of net profit in the Apr 26 quarter. Full-year FY25 profit was $0.1 B. The operating margin ran 4.3% in the latest quarter. — as of 5 August 2026.
What is Amentum Holdings, Inc.'s market cap?
Amentum Holdings, Inc.'s market capitalisation is $6.0 B at a stock price of $24.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Amentum Holdings, Inc.'s P/E ratio?
Amentum Holdings, Inc. trades at a P/E of 40.3×, at the 18th percentile of its own 1-year range, against a long-run median of 72.2×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Amentum Holdings, Inc. pay a dividend?
No — Amentum Holdings, Inc. has declared no dividend per share in any of its last 11 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is Amentum Holdings, Inc. overvalued?
On its own history, Amentum Holdings, Inc. looks cheap against its own history: its P/E of 40.3× has been cheaper only 18% of the time in 1 years (long-run median 72.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
How is Amentum Holdings, Inc. performing?
Amentum Holdings, Inc. is building a base, 16 weeks in. Against the S&P 500 it has been behind on a trailing-13-week view for 22 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is Amentum Holdings, Inc. in an uptrend?
No — the price is building a base (week 16 of stage 1), trading −8.9% versus its 200-day average and at 23% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Amentum Holdings, Inc. beating the market?
Not lately — on a trailing-13-week view Amentum Holdings, Inc. is currently behind the S&P 500 (22 weeks and counting; last ahead the week of 2026-03-06), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.9 years the stock moved −6% against the S&P 500's +35% — behind the index over the full window. — as of 5 August 2026.
Will Amentum Holdings, Inc.'s stock price go up?
This page publishes no price forecast for Amentum Holdings, Inc. What it measures instead: the stock price is $24.1, the price is building a base 16 weeks in. Its P/E of 40.3× sits at the 18th percentile of its own 1-year range. — as of 5 August 2026.
Is the market betting against Amentum Holdings, Inc.?
Somewhat — short interest is 8.8% of Amentum Holdings, Inc.'s tradable float, about 6.5 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Amentum Holdings, Inc. have too much debt?
It is moderate — Amentum Holdings, Inc.'s debt-to-equity is 0.84. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Amentum Holdings, Inc.'s capex?
Amentum Holdings, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Amentum Holdings, Inc.'s cash flow?
Amentum Holdings, Inc. generated $0.5 B of operating cash flow in FY25 and $0.5 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Amentum Holdings, Inc.'s profit real cash?
Yes — over the last 2 fiscal years, 878% of Amentum Holdings, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.5 B against reported profit of $0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Amentum Holdings, Inc.?
On the balance sheet, the Z-score reads 2.07 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.
Where is Amentum Holdings, Inc. in its business cycle?
Amentum Holdings, Inc.'s FY25 operating margin was 3.3%, against a 5-year band of 0.8%–3.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 4.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Amentum Holdings, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Amentum Holdings, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Amentum Holdings, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.